Structure Therapeutics Inc. financial data

Symbol
GPCR on Nasdaq
Industry
Pharmaceutical Preparations
Location
611 Gateway Blvd Suite 223, South San Francisco, CA
State of incorporation
Cayman Islands
Fiscal year end
December 31
Former names
ShouTi Inc. (to 5/13/2022)
Latest financial report
10-Q - Q3 2024 - Nov 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.67K % +103%
Debt-to-equity 4.4 % -62.7%
Return On Equity -16.4 % +71.9%
Return On Assets -15.7 % +59.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 172M shares +23.4%
Common Stock, Shares, Outstanding 172M shares
Entity Public Float 502M USD
Common Stock, Value, Issued 17K USD
Weighted Average Number of Shares Outstanding, Basic 172M shares +49.3%
Weighted Average Number of Shares Outstanding, Diluted 172M shares +49.3%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 95.4M USD +63.2%
General and Administrative Expense 46.8M USD +77.8%
Operating Income (Loss) -142M USD -67.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -111M USD -44.5%
Income Tax Expense (Benefit) -138K USD -138%
Net Income (Loss) Attributable to Parent -111M USD -43.6%
Earnings Per Share, Basic -0.72 USD/shares +60.4%
Earnings Per Share, Diluted -0.72 USD/shares +60.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 172M USD +240%
Cash, Cash Equivalents, and Short-term Investments 915M USD +346%
Assets, Current 924M USD +340%
Property, Plant and Equipment, Net 3.74M USD +55.1%
Operating Lease, Right-of-Use Asset 4.01M USD +9.75%
Other Assets, Noncurrent 1.82M USD +421%
Assets 933M USD +331%
Accounts Payable, Current 8.45M USD +155%
Employee-related Liabilities, Current 6.11M USD +80.6%
Liabilities, Current 33.4M USD +66.4%
Operating Lease, Liability, Noncurrent 2.67M USD -11.9%
Other Liabilities, Noncurrent 309K USD +9.96%
Liabilities 36.4M USD +55.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax 2.84M USD
Retained Earnings (Accumulated Deficit) -293M USD -60.7%
Stockholders' Equity Attributable to Parent 897M USD +365%
Liabilities and Equity 933M USD +331%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -34.1M USD -67.8%
Net Cash Provided by (Used in) Financing Activities 702K USD -99.6%
Net Cash Provided by (Used in) Investing Activities 1.42M USD
Common Stock, Shares Authorized 500M shares
Common Stock, Shares, Issued 172M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -32M USD -132%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 172M USD +240%
Deferred Tax Assets, Valuation Allowance 51.6M USD +85.8%
Deferred Tax Assets, Gross 52.8M USD +89.1%
Operating Lease, Liability 4.39M USD +13.9%
Depreciation 222K USD +217%
Payments to Acquire Property, Plant, and Equipment 162K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -107M USD -39.2%
Lessee, Operating Lease, Liability, to be Paid 4.8M USD +8.85%
Property, Plant and Equipment, Gross 5.1M USD +71.1%
Operating Lease, Liability, Current 1.71M USD +110%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.94M USD +44.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.99M USD +49.7%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 411K USD -25.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 382K USD -70.3%
Deferred Tax Assets, Operating Loss Carryforwards 29.2M USD +54.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 100M shares 0%
Unrecognized Tax Benefits 877K USD +203%
Lessee, Operating Lease, Liability, to be Paid, Year Four 384K USD
Operating Lease, Payments 300K USD +200%
Additional Paid in Capital 1.19B USD +216%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 1.22M USD +637%
Share-based Payment Arrangement, Expense 15.1M USD +124%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%